Mihai I. Truica

Internal Medicine
240 E Huron St
Suite 1-200
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

A bivalent lysine-acetylated small-molecule binding site in MYC.

A bivalent lysine-acetylated small-molecule binding site in MYC.

Journal: bioRxiv : the preprint server for biology
Published: March 18, 2026

Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors.

Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors.

Journal: Science advances
Published: July 16, 2025

Heterobifunctional proteomimetic polymers for targeted protein degradation.

Heterobifunctional proteomimetic polymers for targeted protein degradation.

Journal: bioRxiv : the preprint server for biology
Published: March 31, 2025

Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS.

Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS.

Journal: Nature communications
Published: March 06, 2024

Asparagine Dependency Is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer.

Asparagine Dependency Is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer.

Journal: Cancer research
Published: September 21, 2023

Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.

Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.

Journal: Cancer
Published: April 26, 2023

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC.

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC.

Journal: Nature communications
Published: August 13, 2022

A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression.

A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression.

Journal: Science advances
Published: April 27, 2022

A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.

A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.

Journal: Cancer research
Published: October 20, 2021

Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors.

Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors.

Journal: Cancer research
Published: September 01, 2020

FIREWORKS: a bottom-up approach to integrative coessentiality network analysis.

FIREWORKS: a bottom-up approach to integrative coessentiality network analysis.

Journal: Life science alliance
Published: August 17, 2020

Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.

Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.

Journal: Nature communications
Published: July 24, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026